It is apparent that although Bezwoda claims merely that he "misrepresented" his results, he undertook detailed fabrication. He clearly describes the treatment regimen/schedule for both the experimental and comparison groups in Table 1 , and in Table 2 Furthermore, there may be evidence in the original publication that Bezwoda's data were falsified, or at the very least, suspicious. The number of complete responses (CR) in control patients with soft tissue metastases is given as four in Table 6 , whereas the total number of CRs in controls is given in Table 5 as only two. The number of CRs in experimental subjects with soft tissue metastases is similarly greater than the total number of CRs in this group.
Bezwoda et al 2 state that 49 patients had "two or more [metastatic] sites" and 41 patients had "more than two sites" (p 2485, column 1). Given that there are a total of 90 patients in the trial, all patients must have had at least two metastatic sites. Yet Table 4 gives the average number of metastatic sites per patient by group as 1.8 and 1.6.
Bezwoda et al also report the P value from the 2 comparing the number of complete responses as "P Ͻ .01." Its correct value is P ϭ 8 ϫ 10 Ϫ7 , which is implausibly small for a trial of this size.
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